Page last updated: 2024-11-05

thalidomide and Cutaneous T-Cell Lymphoma

thalidomide has been researched along with Cutaneous T-Cell Lymphoma in 5 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research Excerpts

ExcerptRelevanceReference
"EORTC 21081 was a randomized phase III study of observation alone versus lenalidomide maintenance (25 mg po for 21 days) after debulking therapy in patients with advanced-stage cutaneous T-cell lymphomas (CTCLs)."9.24A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. ( Bagot, M; Beylot-Barry, M; Chaby, G; Cowan, R; Dalle, S; Fox, CP; Hasan, B; Jonak, C; Knobler, R; Marreaud, S; Morris, S; Quaglino, P; Ritchie, D; Romero, PLO; Scarisbrick, J; Servitje, O; Shah, E; Stadler, R; Väkevä, L; Vermeer, MH; Whittaker, S, 2017)
"EORTC 21081 was a randomized phase III study of observation alone versus lenalidomide maintenance (25 mg po for 21 days) after debulking therapy in patients with advanced-stage cutaneous T-cell lymphomas (CTCLs)."5.24A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. ( Bagot, M; Beylot-Barry, M; Chaby, G; Cowan, R; Dalle, S; Fox, CP; Hasan, B; Jonak, C; Knobler, R; Marreaud, S; Morris, S; Quaglino, P; Ritchie, D; Romero, PLO; Scarisbrick, J; Servitje, O; Shah, E; Stadler, R; Väkevä, L; Vermeer, MH; Whittaker, S, 2017)
"Thalidomide and analogues are a class of immunomodulatory drugs or IMiDS."2.46Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders. ( Ladizinski, B; Levis, WR; Sanchez, MR; Shannon, EJ, 2010)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bagot, M1
Hasan, B1
Whittaker, S1
Beylot-Barry, M1
Knobler, R1
Shah, E1
Marreaud, S1
Morris, S1
Dalle, S1
Servitje, O1
Cowan, R1
Väkevä, L1
Chaby, G1
Jonak, C1
Fox, CP1
Ritchie, D1
Vermeer, MH1
Stadler, R1
Romero, PLO1
Scarisbrick, J1
Quaglino, P1
Quintanilla-Martinez, L1
Ridaura, C1
Nagl, F1
Sáez-de-Ocariz, M1
Durán-McKinster, C1
Ruiz-Maldonado, R1
Alderete, G1
Grube, P1
Lome-Maldonado, C1
Bonzheim, I1
Fend, F1
Beltrán, BE1
Maza, I1
Moisés-Alfaro, CB1
Vasquez, L1
Quiñones, P1
Morales, D1
Sánchez, G1
Paredes, G1
Oscanoa, M1
Gerónimo, J1
Miranda, RN1
Castillo, JJ1
Ladizinski, B1
Shannon, EJ1
Sanchez, MR1
Levis, WR1
Oxberry, SG1
Johnson, MJ1

Reviews

1 review available for thalidomide and Cutaneous T-Cell Lymphoma

ArticleYear
Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders.
    Journal of drugs in dermatology : JDD, 2010, Volume: 9, Issue:7

    Topics: Behcet Syndrome; Dermatitis; Erythema Nodosum; Humans; Immunomodulation; Lupus Erythematosus, Cutane

2010

Trials

1 trial available for thalidomide and Cutaneous T-Cell Lymphoma

ArticleYear
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs.
    European journal of dermatology : EJD, 2017, Jun-01, Volume: 27, Issue:3

    Topics: Aged; Angiogenesis Inhibitors; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free

2017

Other Studies

3 other studies available for thalidomide and Cutaneous T-Cell Lymphoma

ArticleYear
Hydroa vacciniforme-like lymphoma: a chronic EBV+ lymphoproliferative disorder with risk to develop a systemic lymphoma.
    Blood, 2013, Oct-31, Volume: 122, Issue:18

    Topics: Adolescent; Child; Child, Preschool; Epstein-Barr Virus Infections; Female; Follow-Up Studies; Herpe

2013
Thalidomide for the treatment of hydroa vacciniforme-like lymphoma: report of four pediatric cases from Peru.
    American journal of hematology, 2014, Volume: 89, Issue:12

    Topics: Adolescent; Child; Female; Humans; Hydroa Vacciniforme; Immunosuppressive Agents; Lymphoma, T-Cell,

2014
Response to thalidomide in chemotherapy-resistant cutaneous T-cell lymphoma.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2006, Volume: 18, Issue:1

    Topics: Aged, 80 and over; Angiogenesis Inhibitors; Female; Humans; Lymphoma, T-Cell, Cutaneous; Thalidomide

2006